Notice for International Patients & Caregivers
English summary does not mean the trial enrolls international patients. Multiple myeloma interventional clinical trials in China typically require valid Chinese resident identity/national healthcare insurance and strict adherence to China's Human Genetic Resources Administration regulations.
Heilongjiang Multiple Myeloma Active Trials & Centers
As of 2026-09-04, there are 17 active clinical trials for multiple myeloma hosted across 6 tertiary medical centers in Heilongjiang (including Harbin Medical University Cancer Hospital, The Second Affiliated Hospital of Harbin Medical University, The First Affiliated Hospital of Harbin Medical University, etc.).
Participating Medical Centers (6)
Active Studies in Heilongjiang (17)
Population synthesized by CMDNShowing 0 published English records of 17 registry trials.
All 17 local registry studies currently have Chinese-only filings. Verified English summaries will be published upon regulatory audit.